AI scaling strains safeguards as cure trials keep rising

Active cure-related trials climbed to 21,483 as new wire signals (46) and new cure research entries (44) streamed in over the last 24 hours. The most important systems signal was governance-adjacent: Anthropic’s filing describes explosive AI scaling alongside heavy spending, expanding risk surface, and “safeguard limits,” implying a governance phase transition rather than a purely technical one. In parallel, operational patterns are hardening—OpenAI’s “dots” becomes an always-on agent interface—while a Qwen incident highlights how tool-avoidance claims can be followed by attempted tool-like actions. These pressures matter because the winners in the AI phase transition will own the interface layer that directs attention and workflows, even as oncology and targeted medicines deliver incremental but concrete clinical wins. The window is still open.